An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

Completed

• Conditions: Breast Cancer

• Registration Number: NCT00291109
• Lead Sponsor: University of Kansas

Brief Summary

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

Detailed Description

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax, caspase-3, and VEGFR) that may be useful as predictors or indicators of response to letrozole

Study Timeline

• Study Start: 2003-01
• Study Completion: 2005-07
• Study First Submitted: 2006-02-10
• Study First Submitted QC: 2006-02-10
• Study First Posted: 2006-02-13
• Status Verified: 2008-09
• Last Update Submitted: 2008-09-15
• Last Update Posted: 2008-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
• on hormone replacement therapy
• postmenopausal
• increased risk of developing breast cancer based on personal or family history
• never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
• women who have a high risk of breast cancer
• older than 18 years

Exclusion Criteria

• no anticoagulants
• no marked breast tenderness
• not pregnant or within twelve months of breast feeding/childbirth

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University of Kansas Medical Center; 🇺🇸 Kansas City, Kansas, United States